Empathogen–entactogen

KA! Empathogenics is a Sponsor and Exhibitor at Wonderland Conference

Retrieved on: 
Saturday, October 28, 2023
Mental health, Empathogen–entactogen, Anxiety, Conference, Nursing

Founder and CEO Stephanie Wang to join Transformative Plants panel

Key Points: 
  • Empathogenics , a company that produces 100% plant-based empathogenic kanna supplements that help people feel more alive, connected and capable, is an official sponsor of the Wonderland Conference that will take place November 9-11 in Miami.
  • KA!
  • Empathogenics will be exhibiting and vending at the conference.
  • Stephanie Wang, the company's founder and CEO, will be participating in the Transformative Plants panel to be held on November 10, at 5pm.

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

Retrieved on: 
Tuesday, June 8, 2021
Psychoactive drugs, Drugs, Hallucinations, Stimulants, Hallucinogen, Dissociative, Dissociative drugs, Euphoriants, Lysergic acid diethylamide, Psychedelic drug, Phencyclidine, Empathogen–entactogen

Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

Key Points: 
  • Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.
  • Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.
  • A r eport from Data Bridge Market Research projected that the psychedelic drugs market is expected to gain market growth in the forecast period of 2021 to 2028.
  • Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2021 to 2028 and is expected to reach USD 6,433.94 Million by 2028.

Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027

Retrieved on: 
Wednesday, April 21, 2021
Psychoactive drugs, Hallucinations, Drugs, Branches of biology, Hallucinogen, Dissociative drugs, Euphoriants, Stimulants, Dissociative, Psychedelic drug, Lysergic acid diethylamide, Empathogen–entactogen

A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027.

Key Points: 
  • A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027.
  • Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027.
  • Psychedelic drugs can be categorized into dissociative drugs (such as PCP), empathogens and serotonergic (classic hallucinogens) (such as LSD).
  • Psychedelic drugs market has increased with increased number of psychedelic drugs as compared to the past few years and increasing prevalence of depression and mental disorders in the U.S.

Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027

Retrieved on: 
Wednesday, April 21, 2021
Psychoactive drugs, Hallucinations, Drugs, Branches of biology, Hallucinogen, Dissociative drugs, Euphoriants, Stimulants, Dissociative, Psychedelic drug, Lysergic acid diethylamide, Empathogen–entactogen

A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027.

Key Points: 
  • A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027.
  • Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027.
  • Psychedelic drugs can be categorized into dissociative drugs (such as PCP), empathogens and serotonergic (classic hallucinogens) (such as LSD).
  • Psychedelic drugs market has increased with increased number of psychedelic drugs as compared to the past few years and increasing prevalence of depression and mental disorders in the U.S.

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Retrieved on: 
Tuesday, August 25, 2020
Psychoactive drugs, Drugs, Receptor agonists, Entheogens, RTT, Hallucinations, Empathogen–entactogen, MDMA, Psychedelic drug, Lysergic acid diethylamide

By combining LSD and MDMA within the same session, the Liechti Lab and MindMed are evaluating if the combination produces greater overall positive acute effects when compared to LSD or MDMA on their own.

Key Points: 
  • By combining LSD and MDMA within the same session, the Liechti Lab and MindMed are evaluating if the combination produces greater overall positive acute effects when compared to LSD or MDMA on their own.
  • MDMA may reduce some of the negative mood effects of LSD and make the patient more comfortable during psychedelic-assisted therapy.
  • President of MindMed, Dr. Miri Halperin Wernli added, "A new treatment paradigm combining MDMA and LSD may enhance the positive effects of LSD by inducing a positive psychological state with MDMA which is an empathogen to help counteract some known negative or less positive aspects of LSD or psilocybin.
  • If MindMed finds the results promising, the company may decide to undertake further studies with treatments combining MDMA and LSD, and prepare patient trials for various indications.